Toboroz
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
NCT07388524· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Eric C. McGary (principal investigator)
Toboroz
Testing Short-Course Radiation Versus Standard-Course Radiation for Soft Tissue Sarcomas That Need Surgery and Radiation
NCT07615049· 3. fázis· SWOG Cancer Research Network· Forrás
Contact: Aakash Batra (principal investigator)
Toboroz
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin
NCT07441681· 3. fázis· NRG Oncology· Forrás
Contact: Gary L. Buchschacher (principal investigator)
Toboroz
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
NCT07215910· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Richard M. Green (principal investigator)
Toboroz
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
NCT07321652· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Ashraf R. Aziz (principal investigator)
Toboroz
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
NCT06592924· 3. fázis· Canadian Cancer Trials Group· Forrás
Contact: Helen H. Moon (principal investigator)
Toboroz
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
NCT06616584· 2/3. fázis· SWOG Cancer Research Network· Forrás
Contact: Eric C. McGary (principal investigator)
Fut, nem toboroz
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT06500455· 3. fázis· NRG Oncology· Forrás
Toboroz
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
NCT06031688· 2. fázis· SWOG Cancer Research Network· Forrás
Toboroz
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
NCT06203600· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Gary L. Buchschacher (principal investigator)
Toboroz
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Helen H. Moon (principal investigator)
Toboroz
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· 3. fázis· NRG Oncology· Forrás
Contact: Sujatha Murali (principal investigator)
Toboroz
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768· 3. fázis· SWOG Cancer Research Network· Forrás
Contact: Sujatha Murali (principal investigator)
Toboroz
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
NCT05642572· 2. fázis· SWOG Cancer Research Network· Forrás
Fut, nem toboroz
Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
NCT05411081· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
NCT05633602· 3. fázis· SWOG Cancer Research Network· Forrás
Fut, nem toboroz
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
NCT05438212· 3. fázis· NRG Oncology· Forrás
Toboroz
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169· 2/3. fázis· NRG Oncology· Forrás
Contact: Gary L. Buchschacher (principal investigator)
Toboroz
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
NCT05058651· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Helen H. Moon (principal investigator)
Fut, nem toboroz
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NCT05095376· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT05096663· 2/3. fázis· SWOG Cancer Research Network· Forrás
Fut, nem toboroz
Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma
NCT04729959· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
NCT05080673· NRG Oncology· Forrás
Contact: Ahmed I. Megahed (principal investigator)
Fut, nem toboroz
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
NCT05050162· 2/3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
NCT04804644· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
NCT04799275· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
NCT04671667· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Aakash Batra (principal investigator)
Fut, nem toboroz
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT04625647· 2. fázis· SWOG Cancer Research Network· Forrás
Toboroz
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
NCT04269902· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Ashraf R. Aziz (principal investigator)
Fut, nem toboroz
EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
NCT04444921· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
A Study of miRNA 371 in Patients With Germ Cell Tumors
NCT04435756· SWOG Cancer Research Network· Forrás
Toboroz
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
NCT04267848· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Eric C. McGary (principal investigator)
Fut, nem toboroz
NCI COVID-19 in Cancer Patients, NCCAPS Study
NCT04387656· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
NCT04134260· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)
NCT04268550· 2. fázis· SWOG Cancer Research Network· Forrás
Fut, nem toboroz
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
NCT04068103· 2/3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT04115631· 2. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Fut, nem toboroz
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
NCT03907488· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
NCT04071457· 3. fázis· SWOG Cancer Research Network· Forrás
Fut, nem toboroz
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
NCT03793166· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
NCT03793179· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
NCT03701282· 3. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445· 2/3. fázis· SWOG Cancer Research Network· Forrás
Contact: Eric C. McGary (principal investigator)
Fut, nem toboroz
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
NCT03737981· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
NCT03660826· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928· SWOG Cancer Research Network· Forrás
Contact: Lara N. Durna (principal investigator)
Fut, nem toboroz
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT03233711· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment
NCT03516942· ECOG-ACRIN Cancer Research Group· Forrás
Fut, nem toboroz
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
NCT03269669· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
NCT02997228· 3. fázis· National Cancer Institute (NCI)· Forrás
Showing 50 of 66.